| Literature DB >> 32367274 |
Jenny Ho1, Davide Sciuscio2, Ulrike Kogel2, Bjoern Titz2, Patrice Leroy2, Gregory Vuillaume2, Marja Talikka2, Elyette Martin2, Pavel Pospisil2, Stefan Lebrun2, Wenhao Xia1, Tom Lee1, Yun Xuan Chng1, Blaine W Phillips1, Emilija Veljkovic2, Emmanuel Guedj2, Yang Xiang2, Nikolai V Ivanov2, Manuel C Peitsch2, Julia Hoeng2, Patrick Vanscheeuwijck3.
Abstract
The use of flavoring substances is an important element in the development of reduced-risk products for adult smokers to increase product acceptance and encourage switching from cigarettes. In a first step towards characterizing the sub-chronic inhalation toxicity of neat flavoring substances, a study was conducted using a mixture of the substances in a base solution of e-liquid, where the standard toxicological endpoints of the nebulized aerosols were supplemented with transcriptomics analysis. The flavor mixture was produced by grouping 178 flavors into 26 distinct chemical groups based on structural similarities and potential metabolic and biological effects. Flavoring substances predicted to show the highest toxicological effect from each group were selected as the flavor group representatives (FGR). Following Organization for Economic Cooperation and Development Testing Guideline 413, rats were exposed to three concentrations of the FGR mixture in an e-liquid composed of nicotine (23 µg/L), propylene glycol (1520 µg/L), and vegetable glycerin (1890 µg/L), while non-flavored and no-nicotine mixtures were included as references to identify potential additive or synergistic effects between nicotine and the flavoring substances. The results indicated that the inhalation of an e-liquid containing the mixture of FGRs caused very minimal local and systemic toxic effects. In particular, there were no remarkable clinical (in-life) observations in flavored e-liquid-exposed rats. The biological effects related to exposure to the mixture of neat FGRs were limited and mainly nicotine-mediated, including changes in hematological and blood chemistry parameters and organ weight. These results indicate no significant additive biological changes following inhalation exposure to the nebulized FGR mixture above the nicotine effects measured in this sub-chronic inhalation study. In a subsequent study, e-liquids with FGR mixtures will be aerosolized by thermal treatment and assessed for toxicity.Entities:
Keywords: E-liquid; Flavor; Inhalation toxicology; OECD; System toxicology
Mesh:
Substances:
Year: 2020 PMID: 32367274 PMCID: PMC7303093 DOI: 10.1007/s00204-020-02759-6
Source DB: PubMed Journal: Arch Toxicol ISSN: 0340-5761 Impact factor: 5.153
Scoring system
| Score | LD50 | Cramer class | Predicted LC50 | Predicted ocular irritancya | Weight of evidence rodent carcinogenicityb | Predicted chronic lowest observed adverse-effect level (LOAEL) | Predicted developmental toxicityc | Volatility |
|---|---|---|---|---|---|---|---|---|
| 2 | Lowest | Class III | Lowest | – | – | Lowest | – | Highest |
| 1 | Second lowest | Class II | Second lowest | True | True | Second lowest | True | Second highest |
| 0 | Others; > 5000 mg/kg | Class I | Others | False | False | Others | False | Others |
aTrue means that it is an irritant
bTrue means that it is a carcinogen
cTrue means that it is toxic
FGR used in this study
| FGR | Flavor group (EC No 1565/2000) |
|---|---|
| Butyric acid | 1A |
| Ethyl acetate, ethyl formate | 1B |
| Isobutyl alcohol | 2 |
| Allyl hexanoate | 3 |
| 4 | |
| 2-Heptanone | 5 |
| Linalool | 6 |
| 8 | |
| 9 | |
| 3-Methyl-2,4-nonanedione | 10 |
| Ethyl maltol | 12 |
| Furaneol | 13 |
| Phenethyl alcohol | 15 |
| Eucalyptol | 16 |
| Eugenyl acetate | 18 |
| 3-(Methylthio)propionaldehyde | 20 |
| 4-( | 21 |
| Cinnamyl alcohol | 22 |
| Methyl salicylate | 23 |
| 2-Ethyl-3,5-dimethylpyrazine | 24 |
| Guaiacol | 25 |
| Methyl anthranilate | 27 |
| 2-Acetylpyridine | 28 |
| 2-Acetylthiazole | 29 |
| Methyl cyclopentenolone (Cyclotene) | 30 |
| 31 |
al-carvone was selected from the flavor list as a representative for aerosol marker and biomarker of exposure
Allocation of rats to exposure groups
| Group | Nicotine (µg/L) | Flavor level | OECD | OECD Plus | |||
|---|---|---|---|---|---|---|---|
| Number of male rats | Number of female rats | Number of male rats | Number of female rats | ||||
| PBS | NA | NA | 10 | 10 | 0 | 0 | |
| PG/VG + Nic | 23 | NA | 10 | 10 | 8 | 8 | |
| PG/VG + F-Med | NA | Medium | 10 | 10 | 8 | 8 | |
| PG/VG + Nic + F-Low | 23 | Low | 10 | 10 | 8 | 8 | |
| PG/VG + Nic + F-Med | 23 | Medium | 10 | 10 | 8 | 8 | |
| PG/VG + Nic + F-High | 23 | High | 10 | 10 | 8 | 8 | |
| PG/VG + Nic (R) a | 23 | NA | 8 | 8 | 0 | 0 | |
| PG/VG + Nic + F-High (R) a | 23 | High | 8 | 8 | 0 | 0 | |
| Total | 76 | 76 | 48 | 48 | |||
a (R) Post-exposure (“recovery”) groups
Characterization of test atmospheres
| Chamber | Droplet size distribution | Nicotine (µg/L) | PG | VG | ||
|---|---|---|---|---|---|---|
| MMAD (µm) | GSD | |||||
| PBS | 1.20–1.41 (15) | 1.54–1.69 (15) | 0.0 ± 0.0 (21) | NM | NM | NM |
| PG/VG + Nic | 1.46–1.99 (15) | 1.68–2.07 (15) | 22.7 ± 1.7 (79) | 1600 ± 153 (80) | 2012 ± 148 (80) | 0.0 ± 0.0 (19) |
| PG/VG + F-Med | 1.46–2.02 (15) | 1.79–1.96 (15) | 0.6 ± 2.7 (23) a | 1656 ± 183 (80) | 2057 ± 214 (80) | 4.0 ± 0.8 (80) |
| PG/VG + Nic + F-Low | 1.57–1.96 (15) | 1.78–2.04 (15) | 22.7 ± 1.9 (80) | 1608 ± 127 (80) | 2016 ± 163 (80) | 1.4 ± 0.5 (80) |
| PG/VG + Nic + F-Med | 1.57–1.95 (15) | 1.84–1.99 (15) | 22.9 ± 2.1 (80) | 1658 ± 160 (80) | 2063 ± 170 (80) | 4.0 ± 0.9 (80) |
| PG/VG + Nic + F-High | 1.57–1.94 (15) | 1.81–1.97 (15) | 22.3 ± 1.6 (80) | 1645 ± 115 (80) | 2057 ± 156 (80) | 6.0 ± 1.3 (80) |
Measurements were performed in the breathing zones of the exposure chambers
Results are presented as mean ± SD; droplet size distribution-related measurements (MMAD and GSD) are presented as range [min–max]
Abbreviations: MMAD, mass median aerodynamic diameter; GSD, geometric standard deviation; NM, not measured
The number of determinants or daily means is given in parentheses
The raw data with values < limit of detection (LOD) were replaced by LOD/2 at the point of statistical calculation to compute the study mean values, except the samples with technical errors
aAll samples were < LOD, except one sample (due to technical error)
Fig. 1Plasma biomarkers of exposure. Results are presented as mean ± SEM for PG (a), -carvone (b), linalool (c), and citronellol (d) concentrations in plasma for male and female rats. Statistically significant differences are represented by empty circles (p ≤ 0.05) or filled circles (p ≤ 0.01) when compared with the groups indicated by the squares underneath the bars
Fig. 2Body weight development. The body weight results for male (top) and female (bottom) rats over time are shown. The results from the similarly exposed OECD, OECD Plus, and Recovery groups were combined for the first 90 exposure days for presentation and for statistical analysis. For additional details, see Table 6
Exposure-related organ weight changes
| Type | Parameter | Sex | Exposed | Recovery | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PG/VG + Nic | PG/VG + F-Med | PG/VG + Nic + F-Low | PG/VG + Nic + F-Med | PG/VG + Nic + F-High | PG/VG + Nic | PG/VG + Nic + F-High | ||||
| Absolute weight after exsanguination | Adrenal gland weight (g) | M | ↥** | ↥ | ↥** | ↥* | ↥ | ↧*** | ↧** | |
| F | ↥*** | ↥ | ↥*** | ↥** | ↥*** | ↧*** | ↧*** | |||
| Brain weight (g) | M | ↧ | ↧ | ↧ | ↧* | ↧ | ↥ | ↥** | ||
| F | ↧ | ↧ | ↧ | ↧ | ↥ | ↥ | ↧ | |||
| Epididymis weight (g) | M | ↥ | ↥ | ↥* | ↥ | ↥ | ↥* | ↥*** | ||
| Heart weight (g) | M | ↥ | ↧ | ↧ | ↧ | ↧ | ↥* | ↥*** | ||
| F | ↥* | ↥ | ↥* | ↥** | ↥** | ↥ | ↧ | |||
| Kidney weight (g) | M | ↧ | ↥ | ↥ | ↥ | ↧ | ↥** | ↥** | ||
| F | ↥ | ↥ | ↥** | ↥** | ↥** | ↥ | ↧ | |||
| Liver weight (g) | M | ↧ | ↧ | ↥ | ↧ | ↧ | ↥** | ↥* | ||
| F | ↥** | ↧ | ↥** | ↥** | ↥*** | ↧* | ↧* | |||
| Lung, larynx, and trachea weight (g) | M | ↧ | ↧ | ↧ | ↥ | ↧ | ↥* | ↥* | ||
| F | ↥ | ↥ | ↥* | ↥* | ↥* | ↥ | ↥ | |||
| Ovary weight (g) | F | ↥** | ↥ | ↥** | ↥ | ↥** | ↧ | ↧ | ||
| Spleen weight (g) | M | ↧* | ↥ | ↧* | ↧** | ↧** | ↥*** | ↥*** | ||
| F | ↥ | ↥ | ↥ | ↥ | ↥ | ↥* | ↥* | |||
| Testes weight (g) | M | ↥ | ↥ | ↥ | ↥ | ↥ | ↥* | ↥* | ||
| Thymus weight (g) | M | ↧* | ↥ | ↧* | ↧** | ↧* | ↥** | ↥* | ||
| F | ↧ | ↥ | ↧ | ↧ | ↧ | ↥** | ↥* | |||
| Thyroid and parathyroid weight (g) | M | ↥ | ↧ | ↧ | ↧ | ↥ | ↧ | ↥ | ||
| F | ↥* | ↥ | ↥ | ↥* | ↥* | ↧ | ↥ | |||
| Uterus and cervix weight (g) | F | ↥ | ↥* | ↧ | ↧* | ↥ | ↥ | ↥* | ||
| Weight relative to body weight | Adrenal gland weight | M | ↥*** | ↥ | ↥*** | ↥** | ↥** | ↧*** | ↧*** | |
| F | ↥** | ↥ | ↥** | ↥ | ↥* | ↧*** | ↧*** | |||
| Brain weight | M | ↥* | ↥ | ↥ | ↥ | ↥ | ↧*** | ↧*** | ||
| F | ↧* | ↧ | ↧*** | ↧*** | ↧** | ↧ | ↧* | |||
| Epididymis weight | M | ↥* | ↥ | ↥* | ↥* | ↥* | ↧ | ↥ | ||
| Heart weight | M | ↥* | ↥ | ↥ | ↥ | ↥ | ↧ | ↧ | ||
| F | ↥ | ↥ | ↥ | ↧ | ↧ | ↧ | ↧* | |||
| Kidney weight | M | ↥ | ↥ | ↥* | ↥* | ↥ | ↧ | ↧ | ||
| F | ↧ | ↧ | ↥ | ↧ | ↥ | ↧ | ↧*** | |||
| Liver weight | M | ↥ | ↥ | ↥* | ↥* | ↥ | ↥ | ↧ | ||
| F | ↥ | ↧* | ↥** | ↥ | ↥ | ↧*** | ↧*** | |||
| Lung, larynx, and trachea weight | M | ↥** | ↥ | ↥* | ↥*** | ↥** | ↧ | ↧*** | ||
| F | ↧ | ↥ | ↧ | ↧ | ↧ | ↧ | ↧ | |||
| Ovary weight | F | ↥ | ↥ | ↥** | ↥ | ↥* | ↧* | ↧ | ||
| Spleen weight | M | ↧ | ↥ | ↧ | ↧ | ↧ | ↥ | ↥** | ||
| F | ↧ | ↥ | ↧ | ↧ | ↧ | ↥ | ↥ | |||
| Testes weight | M | ↥ | ↥ | ↥ | ↥ | ↥* | ↧* | ↧** | ||
| Thymus weight | M | ↧ | ↥ | ↧ | ↧* | ↧ | ↥ | ↥ | ||
| F | ↧* | ↥ | ↧* | ↧* | ↧* | ↥** | ↥* | |||
| Thyroid and parathyroid weight | M | ↥ | ↧ | ↥ | ↧ | ↥ | ↧ | ↧ | ||
| F | ↥ | ↥* | ↥ | ↥ | ↥ | ↧ | ↧ | |||
| Uterus and cervix weight | F | ↥ | ↥* | ↧* | ↧** | ↧ | ↥ | ↥ | ||
| Weight relative to brain weight | Adrenal gland weight | M | ↥** | ↥ | ↥** | ↥* | ↥* | ↧*** | ↧** | |
| F | ↥*** | ↥ | ↥*** | ↥** | ↥*** | ↧*** | ↧*** | |||
| Epididymis weight | M | ↥ | ↥ | ↥* | ↥ | ↥ | ↥* | ↥*** | ||
| Heart weight | M | ↥ | ↥ | ↧ | ↧ | ↧ | ↥* | ↥** | ||
| F | ↥* | ↥ | ↥** | ↥** | ↥* | ↥ | ↧ | |||
| Kidney weight | M | ↧ | ↥ | ↥ | ↥ | ↧ | ↥** | ↥* | ||
| F | ↥ | ↥ | ↥** | ↥** | ↥* | ↥ | ↧ | |||
| Liver weight | M | ↧ | ↧ | ↥ | ↥ | ↧ | ↥** | ↥ | ||
| F | ↥** | ↧ | ↥*** | ↥** | ↥** | ↧ | ↧ | |||
| Lung, larynx, and trachea weight | M | ↥ | ↧ | ↥ | ↥ | ↥ | ↥* | ↥ | ||
| F | ↥* | ↥ | ↥* | ↥ | ↥ | ↥ | ↥ | |||
| Ovary weight | F | ↥** | ↥ | ↥*** | ↥* | ↥** | ↧ | ↧ | ||
| Spleen weight | M | ↧ | ↥ | ↧ | ↧* | ↧* | ↥*** | ↥*** | ||
| F | ↥ | ↥* | ↥ | ↥ | ↥ | ↥* | ↥** | |||
| Testes weight | M | ↥ | ↥ | ↥ | ↥ | ↥ | ↥ | ↥ | ||
| Thymus weight | M | ↧* | ↥ | ↧* | ↧* | ↧* | ↥** | ↥* | ||
| F | ↧ | ↥ | ↧ | ↧ | ↧ | ↥** | ↥* | |||
| Thyroid and parathyroid weight | M | ↥ | ↧ | ↧ | ↧ | ↥ | ↧ | ↥ | ||
| F | ↥* | ↥* | ↥ | ↥* | ↥* | ↧ | ↥ | |||
| Uterus and cervix weight | F | ↥ | ↥* | ↧ | ↧* | ↥ | ↥* | ↥* | ||
Symbols, ↓ indicates response lower in Exposed relative to PBS (measured at identical time point); = indicates no difference; ↑ indicates response higher in Exposed relative to PBS (measured at identical time point); while the Recovery groups are compared against the same treatment group from Exposed
Significance: *p < 0.05; **p < 0.01; ***p < 0.001
M male, F female
For detailed data, see Supplemental Table 13
Food consumption and terminal body weight
| Parameter | Sex | Exposed | Recovery | ||||||
|---|---|---|---|---|---|---|---|---|---|
| PBS | PG/VG + Nic | PG/VG + F-Med | PG/VG + Nic | PG/VG + Nic | PG/VG + Nic | PG/VG + Nic | PG/VG + Nic | ||
| Terminal body weight (g)a | M | 424.8 ± 11.23 (18) | 384.8 ± 5.43 (18)** | 411.5 ± 14.92 (18) | 391.3 ± 10.25 (18)* | 382.9 ± 6.95 (18)** | 382.7 ± 7.89 (18)** | 490.9 ± 19.17 (8)*** | 500.1 ± 26.77 (8)** |
| F | 246.4 ± 4.80 (18) | 272.9 ± 6.13 (18)** | 245.7 ± 4.39 (18) | 279.6 ± 5.36 (18)*** | 286.8 ± 6.11 (18)*** | 278.8 ± 5.31 (18)*** | 288.9 ± 7.60 (8) | 297.0 ± 7.02 (8) | |
| Food consumption (g/day/100 g of body weight) | M | 6.74 ± 0.341 (12) | 7.18 ± 0.198 (14) | 6.78 ± 0.217 (13) | 7.37 ± 0.202 (13) | 7.07 ± 0.196 (13) | 7.07 ± 0.176 (14) | 6.25 ± 0.227 (5)* | 5.98 ± 0.241 (5)** |
| F | 7.53 ± 0.141 (12) | 8.02 ± 0.111 (14)* | 7.22 ± 0.185 (13) | 8.16 ± 0.220 (13)* | 8.15 ± 0.148 (13)** | 8.39 ± 0.196 (14)** | 7.30 ± 0.333 (5) | 6.81 ± 0.279 (5)** | |
Results represent mean ± SEM. The sample size is in parentheses
The Exposed groups are compared against PBS during “Exposed,” while the Recovery groups are compared against the same treatment group from “Exposed.” Significance: *p < 0.05; **p < 0.01; ***p < 0.001
M male, F female
aThe body weights presented were collected on study day 91 during “Exposed” and study day 138 during “Recovery.”
Fig. 3Effects on lung inflammation. The total number of free lung cells recovered from the OECD groups (a) and heat map of multiple analyte profile (listed on y-axis) in BALF (b). Statistically significant differences are represented by empty circles (p ≤ 0.05) or filled circles (p ≤ 0.01) when compared with the groups indicated by the squares underneath the bars. The numbers in the heat map represent the fold increase relative to the PBS-exposed rats (of similar sex), and significance is indicated using the color scale. For details, see Supplemental Table 12
Fig. 4Effects on respiratory organs. The absolute lung (with larynx and trachea) weights (a), lung weights (with larynx and trachea) relative to body weights (b), and histopathology of the larynx (metaplasia at epiglottis base and infiltration at lamina propria) (c–d), and histopathology of the lung (macrophage aggregation at alveolar and infiltration of mononuclear or mixed cell at alveolar or perivascular) (e–f). Statistically significant differences are represented by empty circles (p ≤ 0.05) or filled circles (p ≤ 0.01) when compared with the groups indicated by the squares underneath the bars
Fig. 5Gene-expression response profiles. Gene-expression comparisons conducted to explore the flavor or nicotine effect (a). Volcano plots representing gene-expression changes in RNE (b, c), lung tissue (d, e), and liver tissue (f, g). For each gene, the log2 fold change is represented on the x-axis, and the statistical significance, as the negative log10 FDR-adjusted p value, is represented on the y-axis. Yellow and cyan dots highlight genes that are statistically significantly upregulated and downregulated, respectively (FDR < 0.05)
Fig. 6Boxplot of Cyp1a1 gene expression in lung. Box plots show the median and the first and third quartiles. In addition, the individual data points are shown as black dots
Fig. 7Exposure-related histopathological changes. The histopathological changes in male rats (left) and female rats (right). Median scores were color-coded as follows: [0–0.5] = “Normal;” [0.5–1.5] = "Minimal;” [1.5–2.5] = “Mild;” [2.5–3.5] = “Moderate;” [3.5–4.5] = “Marked; [4.5–5.0] = “Severe.” For exposed groups, the asterisk indicates a statistically significant (p < 0.05) difference from the PBS group. For recovery groups, the asterisk indicates a statistically significant (p < 0.05) difference from the respective same treatment group during Exposed. Note: signs in the “Normal” fields indicate significantly lower scores/incidences than observed in the comparing group. For a detailed presentation of all histological findings, see Supplemental Table 14